Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

14 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Clinical study results of DAS181 against H1N1 influenza presented

NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.

14 Sep 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

Prevention and treatment of pneumonia are critical to reducing child mortality

New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.

14 Sep 2009

Reme-Flu secured as trade name for Nuvilex's homeopathic flu remedy

Nuvilex, Inc., announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the company that Reme-Flu has been secured as the trade name for its homeopathic remedy for helping to prevent and treat flu-like symptoms resulting from influenza, including swine flu.

14 Sep 2009

Practical tips for parents on H1N1 and seasonal flu infections

With the early onset of flu season coinciding with the start of school this year, concern about the flu, and in particular the H1N1 strain of the flu, is growing among parents. Experts from The Children’s Hospital in Denver, Colo., can offer a pediatric perspective on all types of flu, including H1N1, also known as swine flu.

14 Sep 2009

Communicable and Chronic Disease and AIDS course on biological agents causing diseases

Indiana State University's exposure this week to the H1N1 virus has one of the school's environmental health sciences professors using the campus as her classroom.

14 Sep 2009

FOCUS 1 and FOCUS 2 clinical trial results released

Forest Laboratories, Inc today presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter Phase III studies of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients.

14 Sep 2009

FDA releases latest listing of consumer health information updates

The U.S. Food and Drug Administration today released its latest listing of consumer health information updates. All articles can be accessed from the agency's Web page for consumers at http://www.fda.gov/ForConsumers/default.htm.

14 Sep 2009

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.

14 Sep 2009

NIAID conducts human clinical trials of 2009 H1N1 influenza vaccines

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, also is conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited. The NIAID trials are testing two different dosages (15 micrograms versus 30 micrograms) and evaluating the immune response to one and two doses of these vaccines.

14 Sep 2009

PEI and OHA to discuss strategies for managing emergency situations

From Sunday, September 13 through Friday, September 18, 2009, health care professionals from across Prince Edward Island, will gather together to discuss best practices and strategies for managing emergency situations.

14 Sep 2009

U.S., Australian researchers say single H1N1 vaccine dose protects adults against virus

The results of clinical trials have shown one dose of the H1N1 (swine) flu vaccine is enough to offer adults protection against the virus, U.S. and Australian researchers said Thursday, the Associated Press reports (Neergaard, 9/11).

11 Sep 2009

Pneumonia-causing diseases kill 1.2m children under 5 annually, Studies say

"Each year 1.2 million children under age 5 die from Streptococcus pneumoniae and Haemophilus influenzae B or Hib," which cause pneumococcal disease and are preventable with vaccines, according to studies published Thursday in the journal Lancet, Reuters reports.

11 Sep 2009

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

The American Lung Association is making it easier for people to get their seasonal flu vaccine this year with the availability of its 2009-2010 Flu Clinic Locator. The largest online directory of public seasonal influenza vaccination clinics is now available at www.flucliniclocator.org.

11 Sep 2009

Bioneutral's broad spectrum antimicrobial eradicates the H1N1 swine flu virus

BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia, demonstrated that Ygiene® antimicrobial diluted 1 to 10 with water can totally eradicated the H1N1 Swine Flu virus in 59 seconds on an unclean, soiled surface.

11 Sep 2009

Results from a preclinical study of Variation's influenza vaccine to be presented at ICAAC meeting

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today announced that it plans to present positive results from a preclinical study of the company’s proprietary influenza vaccine at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held at the Moscone Convention Center in San Francisco, California.

11 Sep 2009

Elderberry extract prevents H1N1 infection in vitro

A recent research study has given new scientific evidence to the long-held empirical belief that elderberries possess antiviral activities. The research involved a specific, reproducible elderberry extract developed by HerbalScience Group LLC, and succeeded in identifying key chemical components of the extract that inhibited in vitro infection and were shown to bind directly to Human Influenza A (H1N1) virus particles. The binding blocked the ability of the viruses to enter host cells, and thereby effectively preventing H1N1 infection in vitro.

11 Sep 2009